EndoBarrier in 90 consecutively treated patients - Abstract
EndoBarrier treatment for longstanding type 2 diabetes and obesity: outcomes one year after EndoBarr
EndoBarrier treatment for longstanding type 2 diabetes and obesity: outcomes one year after EndoBarr
Covid-19 Meta-analysis
Comparing 9- vs 12-Month Implantation in the Worldwide EndoBarrier (EB) Registry
Authors:
REJ Ryder, M Yadagiri, L Munro, H Frydenberg, S Fishman, JP Byrne, JP Teare, C De Jonge, JW Greve, JJ McMaster, J Chisholm, L Kow, JC Mason, J Stein, RV Cohen, P Sen Gupta.
Duodenal Jejunal Bypass Liner (DJBL) treatment for type 2 diabetes and obesity: glycaemic and CVD risk factor improvements vs risks among 1068 patients treated worldwide.
Authors:
R.E.J. Ryder, J. Stein, T. Battelino, J. Teare, A. Ruban, H. Frydenberg, L. Munro, S. Fishman, R. Cohen, C. de Jonge, J.-W. Greve, H. Sourij, P. Sen Gupta1, K. Laubner, J. Seufert.
In the third of the 2023 ABCD webinar series, please join Professor Paul Cockwell to discuss management of chronic kidney disease in patients with type 2 diabetes.